Investment Rating - The industry investment rating is maintained at "Overweight" [2][9]. Core Insights - The vaccine industry is experiencing a transition from scale expansion to innovation-driven growth, with short-term pain due to supply-demand imbalance and homogenized competition, but the long-term positive outlook remains unchanged [9][27]. - Recent advancements in vaccine technology and policy changes are expected to drive demand, particularly with the expansion of the immunization program for Japanese encephalitis vaccines in certain regions [4][9]. - Companies like Zhifei Biological are making significant progress with new vaccine candidates, including an mRNA vaccine for shingles and a lyophilized inactivated vaccine for chickenpox, which could enhance their competitive edge [4][9]. Summary by Sections Industry Performance - The vaccine sector has seen a cumulative decline of 11.36% since 2025, with a recent weekly drop of 1.42% [5][11]. - Relative performance against the CSI 300 index shows a decline of 29% over the past 12 months [4]. Company Developments - Zhifei Biological has received clinical trial approval for two new vaccines, indicating progress in both mRNA and inactivated vaccine technologies [4]. - The company is focusing on innovative vaccine development to enhance its product pipeline and market competitiveness [9]. Market Dynamics - The vaccine industry is currently facing challenges such as high competition among Me-too products and a decline in demand due to consumer hesitancy [8][24]. - The industry is expected to adjust its pipeline strategies, emphasizing innovation and multi-valent products to improve market positioning [8][24]. Valuation Metrics - The vaccine sector's price-to-earnings (PE) ratio is reported at 65.37X, with a recent decrease of 1.47X, while the price-to-book (PB) ratio stands at 1.21X [7][19]. - The PE ratio is at the 55.06% percentile since 2013, indicating a relatively high valuation compared to historical data [7]. Investment Recommendations - The report suggests focusing on companies with strong research and innovation capabilities, particularly those with differentiated product offerings, such as CanSino [9][27]. - Long-term investment opportunities are anticipated in the context of innovation and international market expansion [8][9].

Core Viewpoint - The company, Zhifei Biological Products (300122), has received clinical trial approval for two vaccines developed by its wholly-owned subsidiary, Zhifei Longkema, indicating a continuous expansion of its vaccine research pipeline [1] Group 1: Vaccine Approvals - On February 3, the company announced the approval of its mRNA vaccine for shingles, which is a product based on its proprietary mRNA technology, marking the first mRNA vaccine approved for clinical trials in China [1] - The shingles mRNA vaccine is noted for its good immunogenicity and high safety profile, effectively preventing the occurrence of shingles [1] - On February 4, the company announced the approval of its lyophilized inactivated varicella vaccine, which utilizes an innovative inactivation technology and is suitable for individuals aged 12 months and older [1] Group 2: Safety and Target Population - The varicella vaccine is designed to provide a safer option for both healthy individuals and those with immune deficiencies or contraindications for vaccination [1] - The company emphasizes that vaccine development involves significant investment, long cycles, and high risks, with uncertainties regarding the clinical trial progress, results, and subsequent approval for production and commercialization [1] Group 3: Financial Impact - The company indicates that the clinical trials for the two vaccines will not have a significant impact on its recent financial performance and will continue to fulfill its information disclosure obligations as required [1]

Policy Developments - Shanghai aims to vigorously cultivate and develop future industries such as brain-computer interfaces and fourth-generation semiconductors, as stated in the government work report presented at the Shanghai Municipal People's Congress [1] Drug and Medical Device Approvals - Novartis announced that its innovative biological drug Cosentyx (secukinumab) has received approval from the National Medical Products Administration in China for a new indication to treat active non-radiographic axial spondyloarthritis in adults who have had an inadequate response to non-steroidal anti-inflammatory drugs [2] - Hualan Biological announced that its recombinant Exendin-4-Fc fusion protein injection (HL08) has received clinical trial approval for use in adult patients with obesity or overweight, expanding its indications beyond type 2 diabetes [3] - Bibet's BEBT-701, a globally first AGT/PCSK9 dual-target siRNA drug, has received approval for clinical trials to treat mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol [4] - Zhifei Biological's mRNA vaccine for shingles has received clinical trial approval from the National Medical Products Administration [5] Financial Data - Yaokang Biological reported a total revenue of 793 million yuan for 2025, a year-on-year increase of 15.49%, and a net profit of 144 million yuan, reflecting a growth of 31.49% [6] Industry Developments - Jichuan Pharmaceutical's wholly-owned subsidiary has signed an exclusive commercialization rights agreement for the Inusimab injection, paying an authorization fee of 80 million yuan [7][8] - Insilico Medicine announced it received a milestone payment of 39 million HKD from Menarini after the MEN2501 project completed its first patient dosing in Phase I clinical trials [9] - WuXi Biologics has signed a licensing and research service agreement with Vertex Pharmaceuticals for an innovative trispecific T cell engager, which will be used to treat B cell-mediated autoimmune diseases [10]

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

智飞生物2月3日公告，公司全资子公司安徽智飞龙科马生物制药有限公司研发的带状疱疹mRNA疫苗获 得国家药品监督管理局药物临床试验批准通知书，同意开展用于预防带状疱疹的临床试验。公司带状疱 疹mRNA疫苗临床试验申请获得批准对公司近期业绩不会产生重大影响，但有利于公司夯实研发技术， 加强在研管线储备。该项目后续临床试验进度、结果及产品上市情况存在不确定性，公司将根据研发进 展情况及时履行信息披露义务。 ...

格隆汇2月3日丨智飞生物(300122.SZ)公布，近日获悉，由全资子公司安徽智飞龙科马生物制药有限公 司（简称"智飞龙科马"）研发的带状疱疹mRNA疫苗获得国家药品监督管理局药物临床试验批准通知书 （通知书编号：2026LP00326），同意开展用于预防带状疱疹的临床试验。 ...

智通财经APP讯，智飞生物(300122.SZ)公告，公司子公司安徽智飞龙科马生物制药有限公司(简称"智飞 龙科马")研发的带状疱疹mRNA疫苗获得国家药品监督管理局药物临床试验批准通知书，同意开展用于 预防带状疱疹的临床试验。 ...

（文章来源：第一财经） 智飞生物公告，由全资子公司智飞龙科马研发的带状疱疹mRNA疫苗获得国家药品监督管理局药物临床 试验批准通知书，同意开展用于预防带状疱疹的临床试验。该疫苗是公司自主知识产权mRNA技术产 品，具有良好的免疫原性和安全性，能够有效预防带状疱疹发生。此次获批将进一步丰富公司成人疫苗 品种，完善产品布局，强化市场地位。 ...

Core Viewpoint - The company is actively developing multiple vaccine technology platforms, including mRNA and novel adjuvant technologies, to achieve innovation and upgrades in vaccine products [2] Group 1 - The company has established an mRNA technology platform and a novel adjuvant technology platform [2] - The company’s subsidiary, Zhifei Longkema, has received a clinical trial acceptance notice from the National Medical Products Administration for its shingles mRNA vaccine [2] - The company aims to explore various vaccine development pathways for iterative upgrades and breakthroughs in vaccine products [2]

Core Viewpoint - The company has developed an mRNA vaccine for shingles, which has received acceptance for clinical trial application from the National Medical Products Administration [1] Group 1 - The company's wholly-owned subsidiary, Zhifei Longkema, is responsible for the research and development of the shingles mRNA vaccine [1] - The clinical trial application for the shingles mRNA vaccine has been officially accepted, indicating progress in the vaccine's development [1]